Solskin
Halozyme Therapeutics (NYSE:HAL) intends to finance its 2B euro ($2.1B) proposed acquisition of Germany’s Evotec (EVO) in money, Bloomberg reported Sunday, quoting Chief Govt Helen Torley.
“We really feel assured in with the ability to fund this as a completely money deal,” Torley